Strategic Australian and APAC Specialist CRO
For founders and clinical leaders of small to mid-sized biotech firms, particularly those in the US and Europe, the mandate is clear: you must deliver high-quality, reliable data rapidly to secure future capital and, more profoundly, validate your science for the sake of patient health.
Success in early-phase development, from first-in-human (FIH) through pivotal Phase II, is the foundation of commercial valuation and the non-negotiable prerequisite for achieving investor readiness. This pivotal stage demands a strategic partner defined by profound local expertise and unwavering accountability.
The Challenge:
In the high-stakes environment of clinical development, the margin for error is low. We help you navigate two primary risks:
Investors seek maximum return on capital and accelerated milestones. Failures to execute—including submission delays or inconsistent data quality—erode funding confidence and threaten the entire capital runway.
Beyond financial viability, the ultimate complication is jeopardizing the scientific mission—risking that promising medical breakthroughs fail to reach the patients who need them.
The Strategic Specialist:
Delivering predictability and precision in early-phase CRO Services
Southern Star Research is the award-winning Strategic Australian Specialist, purpose-built to transform complex early-phase trials into robust, commercially attractive, and scientifically defensible assets.
Trials conducted in Australia offer estimated expenditures up to 60% lower than the US or EU.
The Australian R&D Tax Incentive provides a cash rebate of up to 43.5% on eligible expenditures.
Streamlined regulatory environments enable initiation timelines as short as 4–8 weeks from submission to site activation.
Generate regulator-ready data recognized by the FDA, EMA, PMDA, and Health Canada.
Partnership Assurance:
We view our function as your trusted advisors, providing the specialized execution required to safeguard scientific outcomes.
Your Project Manager is assigned at contract and stays accountable through final database lock, reducing handover risk.
We stress-test protocols before they reach the site and flag regulatory sensitivities before they become submission delays.
Our 4–8 week initiation times are driven by longstanding relationships with Phase 1 units, labs, and logistics providers across Australia.
While we focus on Phase I and II, our international relationships ensure seamless progress to later phases when your program demands it.
Domain expertise in complex indications
Our team generates data that stands up to global scrutiny across indications essential for de-risking your program:
Specialised experience in central nervous system disorders.
Proven expertise in early-phase dermatology trials across inflammatory and immune-mediated conditions.
Extensive experience conducting first-in-human and Phase I studies with healthy volunteer populations.
Deep capability in metabolic and cardiovascular trials across diverse patient populations.
Expert navigation of early-phase oncology and immuno-oncology settings across multiple tumor types.
Specialised support for rare disease programs requiring tailored trial designs and patient recruitment strategies.
Experienced in reproductive and sexual health trials across diverse study populations.
Comprehensive expertise in vaccine and infectious disease trials with strong site and logistics networks.
Discover why capital-focused leaders choose Southern Star Research to protect their program and their runway.